SWISS COMPANIES Acino Pharma Acino (SIX: ACIN), a Swiss-based pharmaceutical company, develops and manufactures generic and

innovative pharmaceuticals using advanced drug delivery technologies, for which it also holds patents. Members of Group Management Peter Burema, CEO Robert Schmid, CFO Dr. Harald Haubitz, Head Production & SCM Dr. Jean-Daniel Bonny, Head of Research & Development Phone +41 61 338 60 91. Fax +41 61 338 60 82 jean-daniel.bonny(at)acinopharma.com Jrg Gebhardt, Head IT & HR Daniel Hossli, Head Group Legal (from November 1, 2011) Ruud van Anraat, Chief Commercial Officer Dr. Ulf-Hergen Westphal, Head Quality Chairman of the Board of Directors Luzi Andreas von Bidder Members of the Board of Directors Hans Peter Hasler, Vice-Chairman Dr. Anders Hrfstrand Jrg Michel Dr. Ren Muttenzer Dr. Andreas Rummelt Honorary Chairman Dr. Hans-Peter Schr Actelion Pharmaceuticals Ltd Phone: +41 61 565 65 65 Fax: +41 61 565 65 00 BOARD OF DIRECTORS Jean-Pierre Garnier Juhani Anttila Jean-Paul Clozel Werner Henrich Armin Kessler Robert Cawthorn Robert J. Bertolini Carl Feldbaum Michael Jacobi Jean Malo

Phone Phone +41 61 338 60 00 Fax +41 61 338 60 80 info(at)acino-pharma.com Acino Holding Ltd. Basle +41 61 338 60 00 Acino Pharma Ltd. Basle +41 61 338 60 00 Acino Pharma Ltd. +41 61 775 80 00 Acino Pharma Ltd. Aesch +41 61 756 40 00 Acino Supply Ltd. Aesch +41 61 756 40 00 Acino AG Miesbach 2867-0 Phone +49 8025 Liesberg

Acino Pharma, Inc. USA +1 (215) 345 7397

Phone: +41 61 565 65 65 Fax: +41 61 565 65 00

Andrew J. Oakley, Chief Financial Officer Bachem is specialized in the process development and the manufacturing of biologically active peptides and complex organic molecules as active pharmaceutical ingredients (APIs) and as innovative biochemicals for research purposes. Dr. Thomas Frh Executive Vice President and COO Bachem AG, Switzerland Dr. Rolf Nyfeler, Chief Executive Officer (CEO) Stephan Schindler, Chief Financial Officer (CFO) Dr. Lester Mills, Chief Marketing Officer (CMO) Dr. Daniel Erne, Chief Technology Officer (CTO) Switzerland HQ Tel +41 61 935 2323/33 Fax +41 61 935 2325 Peptide research and development +41 61 935 2333 Development and manufacturing of active pharmaceutical ingredients (API) +41 24 482 4444

Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland, and listed on the SIX Swiss Exchange (SIX:BSLN). Its fully integrated research and development operations are currently focused on antibiotics and antifungals, as well as on the development of dermatology and oncology drugs, targeting the medical challenge of resistance and non-response to current treatment options in the hospital and specialty care setting Management Committee Dr. Anthony Man Dr. Ingrid Heinze-Krauss Prof. Achim Kaufhold Dr. Laurenz Kellenberger Mr. Hans Christian Rohde Mr. Ronald Scott

Basilea Pharmaceutica Ltd. Grenzacherstrasse 487 PO Box 4005 Basel Switzerland T: +41 61 606 11 11 F: +41 61 606 11 12 email: info_basilea@basilea.com

Telephone: +49 (40) 4909-0 Fax: +49 (40) 4909-3434 Beiersdorf AG Focus on Skin Care. Closer to Markets. These two elements form Beiersdorfs consumer business strategy. Skin care is our key competence since 130 years and also today the focus of all our efforts. With closeness to the markets we are able to identify local consumer wishes quickly and align ourselves precisely with the respective market development. Dr. Walter Diembeck, Hamburg Research chemist, Beiersdorf AG Switzerland +41-61-415 6111 +41-61-415 6332 Laboratoires La Prairie SA +41-44-9478282 +41-44-9478180

BHLMANN Laboratories AG

CARBOGEN AMCIS is a leading provider of drug development and commercialization services to the pharmaceutical and biopharmaceutical industries, at all stages of drug development. The integrated services of CARBOGEN AMCIS provide innovative, timely and safe drug development solutions that allow customers to make the best use of their available resources. Sales Manager Europe Dr Thomas Schlatterer Fax: (+41) 628-89 36 10 (+41) 628-89 36 42 Mobile: (+41) 795-93 26 48

Switzerland Fon: +41 61 487 12 12 Fax: +41 61 487 12 34 info@buhlmannlabs.ch HQ Switzerland Tel: (+41) 61-935 53 53 Fax: (+41) 61-935 53 00

UK and Scandinavia Sonal Naik Tel: Fax: (+41) 619-35 53 00 Mobile: (+44) 752-596 55 30

France, Belgium, Southern Europe and Middle East Jocelyn Saget Tel: (+33) 241-69 26 83 Fax: (+33) 241-69 26 83 Mobile: (+33) 672-59 35 03 Central Europe North Dr Alexander Strtz Fax: (+49) 2207-919 91 93 Tel: (+49) 2207-70 17 97 Mobile: (+49) 162-426 24 35

Pascal Villemagne as vice president commercial Mark Griffiths, CEO

Dishman is a global, dynamic group of companies offering a continuum of services to the pharmaceutical industry. We are a global outsourcing partner for pharmaceutical companies, offering a portfolio of products and development, scale-up and manufacturing services. Jay. R. Vyas, Managing Director Dr Denish Shah GENERAL MANAGER R&D Dr Rajiv Desai PRESIDENT QUALITY Custom Services Director Christian Dowdeswell Tel: +44 (0)17 4473 0867 Fax: +44 (0)17 4445 1141 christian.dowdeswell@dishmangroup.com

Manufacturing Sites India Ahmedabad India Tel.: +91 2717 302400 Fax: +91 2717 302499 dishman@dishmangroup.com Dishman Pharmaceuticals and Chemicals Ltd. Ahmedabad, India Tel: +91 (0)79 2282 0103 Fax: +91 (0)79 22821633 dishman@dishmangroup.com China Shanghai Dishman Pharmaceuticals and Chemicals (Shanghai) Co., Ltd. Tel: +86 21 6712 1166 Fax: +86 21 6712 0811 sales@dishman.net.cn Netherlands Dishman Netherlands B.V. Tel: +31 (0)318 545 754 Fax: +31 (0)318 529 374 info@dishman-netherlands.com CARBOGEN AMCIS Head Office Tel: (+41) 61-935 53 53 Fax: (+41) 61-935 53 00 info@carbogen-amcis.com Aarau Switzerland Tel: (+41) 62-836 48 00 Fax: (+41) 62-836 48 10 Neuland Switzerland Tel: (+41) 62-889 36 00 Fax: (+41) 62-889 36 10 United Kingdom Tel: (+44) 161-223 33 44 Fax: (+44) 161-220 87 78 Tel: +41 61 935 53 23 Fax: +41 61 931 27 17 Christoph.Schaefer@cis-pharma.com

Sales Manager (Central & Eastern Europe) Michael Exner Tel: +49 176 2072 1806 Fax: +44 207 323 0609 michael.exner@dishmangroup.com Sales Manager (Western Europe) Jean-Pierre Onckelet Tel: +33 1 48 61 95 14 Fax: +44 207 323 0609 jean-pierre.onckelet@dishmangroup.com

CIS Pharma is a pharmaceutical research company specialised in drug delivery. We develop novel treatments in the fields of ophthalmology and dermatology. We are innovators patenting New Chemical Entities, Drug Delivery Systems and Medical Devices with a strong scientific and commercial rationale. Christoph Schfer, CEO Doris Schfer, CFO Hans Hitz, R & D Rolf Schfer, Corporate Strategy and Innovation

Evolva Pharmaceuticals Our emphasis is on small-molecule compounds that can be delivered orally. EV-077 for the treatment of complications of diabetes EV-077 & EV-075 for the treatment of viral infections EV-021 for the treatment of bacterial infections EV-009 for the treatment of bacterial infections EV-086 for the treatment of fungal infections Neil Goldsmith CEO and Managing Director Dr. Alexandra Santana Sorensen President Jakob Dynnes Hansen, MBA Chief Financial Officer Prof. Dr. Jutta Heim Chief Scientific Officer Dr. Norbert Bender Chief Medical Officer Dr. Panchapagesa Murali Managing Director & CEO, Evolva India Dr. Pascal Longchamp Chief Business Officer Dr. Simon Waddington CEO, Evolva Nutrition Inc. Isabelle Stcklin PA to the CEO isabelles@evolva.com +41 61 485 2006 Tel: +41 61 485 2000 fax: +41 61 485 2001

GABA International AG is a European branded manufacturer of innovative, top-quality oral care products. GABA has been collaborating closely with dental professionals for over 50 years. Ms. Christiane Spiegelhalder Head of Scientific Affairs Department

Switzerland Phone +41 61 415 60 60 Fax +41 61 415 60 00

Midatech Ltd
Midatech is at the forefront of designing, developing, synthesizing and manufacturing nanomedicines based on its proprietary, self assembling biocompatible nanoparticle technology. Professor Thomas Rademacher Chairman and CEO Storme Moore-Thornicroft Vice President, Corporate Management T: +44 1235 528 022 The companys corporate capabilities are further supported by the following wholly owned subsidiaries: Midatech US, Pharmida AG and Midatech Biogune S.L. Business Development, Partnering and Licensing Europe Peter Sorg T: + 41 797 079 464 Midatech US Sterling Johnson President T: +1 760 936 1024 Drug Development Jan Mous Pharmida AG CEO T: + 41 793 522 314

HQ +44 1235 528 022 F: + 44 1235 528 023

cGMP Manufacturing and Research Midatech Biogune S.L. Justin Barry CEO T: + 34 944 034 020

Genedata transforms data into intelligence with innovative software solutions that support large-scale, experimental processes in life science research. Founded in 1997, Genedata delivers enterprise solutions for data analytics that streamline R&D workflows and improve research productivity

Switzerland Tel: +41 61 511 8400 Fax: +41 61 511 8484 Germany Tel: +49 89 4581 9010 Fax: +49 89 4581 9015

Dr. Othmar Pfannes CEO Dr. Hans Peter Fischer Head of Genedata Phylosopher Business Unit Dr. Stephan Heyse Head of Genedata Screener Business Unit Dr. Jens Hoefkens Head of Genedata Expressionist Business Unit Dr. Kurt Zingler Managing Director USA Dr. Peter Haberl Managing Director Germany Hideki Shimohiro Managing Director Japan Karger a Life sciences Publishing agency devoted to printing books for sciences Congress announcements, invitations to exhibitions Exhibition Coordinator Monika Willin (m.willin@karger.ch) +41 61 306 11 11 (switchboard) BioResearch Lonza comprises the areas of Cell and Molecular Biology, Drug Discovery and applied research as well as quality control laboratory testing systems including tools for quality control tests for microbial detection. Stefan Borgas Uwe H. Bhlke Toralf Haag CEO Member of board Member of Board General Contacts for Lonza Custom Manufacturing HQ Tel +41 61 316 81 11 Fax +41 61 316 91 11 North America Tel +1 201 316 9200 custom@lonza.com Europe & Rest Of World Tel +41 61 316 8111 custom@lonza.com\

MEPHA PHARMA AG Anti-allergics Acne, antimycotics Anti-infectives, anti-malarials Anti-diarrhoeals, anti-ulcer Dr. Jrgen Betzing Senior Director Tech Ops Generics Europe Dr. Victor Brantl Vice President Generics Development Europe

Tel: +41 (0) 61 705 43 43 Fax +41 (0) 61 705 43 85

Mondobiotech is an unconventional drug discovery company dedicated to treating rare and neglected diseases, some of them chronic, many of the them life-threatening. Mondobiotech (SIX Swiss Exchange RARE) is a Swiss research company focused on finding treatments for rare and neglected diseases. Paolo Bassanini, Investor & External Relations Ruggero Gramatica CEO and Board Member Dr. habil. Dorian Bevec CSO and Founder Paolo Barbieri CFO Maria Teresa D'Antonangelo Bhlmann Corporate Affairs & Business Support David Cox Head of BD&L Novartis Stefan Hartmann Head Clinical Operation Manager therapeutic area of Immunology and Infectious Diseases Joseph Jimenez, Chief Executive Officer of Novartis AG Dr. Jrgen Geiger Brokatzky Head of Human Resources David Epstein, Division Head, Novartis Pharmaceuticals Armin J. Zust Head of Novartis Switzerland Dr. Dr. Oswald Division Head, Novartis Vaccines and Diagnostics

Tel Fax:

+41 (0)840 20 00 10 +41 (0)840 20 00 11

Novartis International AG Basel Switzerland Phone +41 61 324 11 11 Fax +41 61 324 80 01

ABAC R&D Ltd. ABAC is interested in complementary partnerships for product development, manufacturing, marketing and distribution. Contact person Dr. Othmar Kaeppeli, Executive Director Company main phone +41 (43) 888 50 50 Company main fax +41 (43) 888 50 12 Website www.abac.ch

PENTAPHARM has a long-standing tradition as an innovative and reliable supplier of active ingredients for the pharmaceutical, diagnostic and cosmetic industry. Our roots as researchers, developers and manufacturers of state-of-the-art products reach back to 1948. PENTAPHARM develops and manufactures reagents and test systems for coagulation and fibrinolysis diagnostics. DSM Nutritional Products AG Fax: +41 61 706 4800 Phone: +41 61 706 4848

Beat Ineichen Director Sales & Marketing Pharma Telefon: +41 706 46 77 Christine Spaenhauer-Horanyi Telefon: + 41 61 706 46 48 Hans van Leeuwen Telefon: +41 61 706 48 32 Matthias Henz Telefon: +41 61 706 47 77 Senior Product Manager

General Manager

Head QM & Regulatory Affairs

Christian Witzig Head of Operations Telefon: +41 61 706 47 51 Thierry Ketterlin Telefon: +41 61 706 46 60 Abel Ferrandez Telefon: +41 61 706 48 84 Chief Financial Officer

Head of R&D

Renata Putnik Head Human Resources Telefon: +41 61 706 46 66

Daniela Tschanz Management Assistant +41 61 706 48 32

Christian H. Lutz, Chairman of the Board The Permamed I founded in 1979. We are now a separate and independent Swiss pharmaceutical company in Switzerland and employs around 60 staff in the development, manufacture, licensing, marketing, and consulting for physicians in practice and clinic as well as in pharmacies and drugstores. Tobias Lutz Peter Bnzli Business dev. manager COO Board Member Permamed AG T +41 (0) 61 725 20 20 F +41 (0) 61 725 20 40 permamed(at)permamed.ch

Dr. Peter Huber, Board Member Medical and Scientific Director and Head of Galenic development

Allemann, Peter Areas of expertise:

Head of Production

Production and Planning Packaging Purchase of raw materials

Polyphor is a Swiss research-driven pharmaceutical company developing innovative products with high therapeutic benefit to the patient and providing high quality support to its industry partners engaged in drug discovery. Executive Committee Jean-Pierre Obrecht Daniel Obrecht Christoph Rentsch Michael Altorfer CEO Klaus Dembowsky Development Chief Medical Officer Marc Thommen Peter Zbinden CSO CFO Head Corporate Development, Head Drug Discovery & Deputy CEO

Polyphor Ltd Hegenheimermattweg 125 CH-4123 Allschwil Switzerland Tel. +41 61 567 16 00 Fax +41 61 567 16 01 info@polyphor.com

Head Technology Platforms Head Internal Services

Proreo Pharma is a privately owned Swiss based specialty pharmaceutical company. With emphasis on the therapeutic areas of central nervous system, gastroenterology, renal care, and surgery, Proreo Pharma focuses on the acquisition, development, and commercialization of innovative specialist medicines. In Switzerland, France and Germany, the company uses its own commercial infrastructure to market its products. Further presence and reach is achieved via a network of distribution partners. Rudolf Syz - Founder & ChairmanSwitzrland Gnter Graubach - Founder & Chief Executive Office GERMANY Dr. Roland Rutschmann - Commercial Director FRANCE Dr. Andreas von Sprecher - Research & Development Director Marius Raulf - Managing Director, Proreo Pharma Germany Sharon Uval Maran - Chief Executive Officer, Prospera Pharma Ltd (Cyprus) Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focusing on the development and marketing of innovative pharmaceutical products for the treatment of neuromuscular and mitochondrial diseases. This area of high unmet medical need includes many orphan and niche indications with no current therapy. Thomas Meier is Chief Executive Officer Klaus Schollmeier, Chairman Martin Gertsch is Chairman Prof. Katharine M. D. Bushby received her doctorate in medicine Dr. Timothy J. Rink is chairman of the strategy panel (board of directors) Prof. Markus A. Regg is Professor for Neurobiology Gnter Metz VP Operations & Alliance Management phone: +41 (0)61 906 89 13 guenter.metz@santhera.com Thomas Staffelbach VP Head Public & Investor Relations phone: +41 (0) 61 906 89 47 Thomas Staffelbach VP Head Public & Investor Relations phone: +41 (0) 61 906 89 47

Phone: +41 61 927 8777 Fax: +41 61 927 8775 Phone: +33 1 42 35 72 80 Fax: +33 1 42 35 45 77 Phone: +49 2102 1016790 Fax: +49 2102 1016791

HQ +41 (0)61 906 89 50 Company Subsidiaries Switzerland phone: +41 (0)61 906 89 50 United States of America phone: +1 617 886 51 61 Germany phone: +49 7621 1690 200 Canada phone: +1 514 448 5186

S.L.A. Pharma is a privately owned company, located outside Basel in Switzerland with an operations arm in the UK. Our dedicated team includes experienced pharmaceutical, medical and regulatory professionals with the required knowledge and expertise to drive the product from conception through to launch. Therapeutic Areas FAP is a genetically inherited condition, which presents as large numbers (maybe hundreds) of polyps in the large intestine... Perianal Crohn's disease is an inflammatory condition that affects the anus and perianal area and is considered to be one of the most

Head Office S.L.A. Pharma AG Switzerland T / +41 61 922 05 11 F / +41 61 922 06 33

+44 (0)1923 681001 F / +44 (0)1923 681221

Biotie is a specialized drug development company focused on the development of drugs for neurodegenerative and psychiatric disorders (Parkinson's disease, Alzheimer's disease and other cognitive disorders, bipolar disorder, and alcohol and drug dependence) Timo Veromaa President & CEO Ian Massey COO Chris Piggott Chief business Officer Zack McNealy Interim CFO Stephen Bandak CMO

Finland Tel. +358 2 274 89 00 Fax +358 2 274 89 10 Switzerland Tel: +41 61 206 9202 Fax: +41 61 206 9201 Tel: +1 650-244-4850 Fax: +1 650-244-4874

Vivendy Therapeutics Ltd. was founded in March 2006, as a spin-off of Inotech Biotechnologies AG. The company's mission is the development of an enzyme replacement therapy (ERT) for Morbus Morquio (Mucopolysaccharidosis (MPS IVA), a rare lysosomal storage disease (LSD) Executive Director Dr.Gosse Bruinsma

Vivendy Therapeutics Ltd. Switzerland Tel: +41-61-271 87 80 Fax: +41-61-271 87 81 web: www.vivendy.ch mail: info[at]vivendy.ch

Director Clinical and Regulatory Affairs Dr. Gertrud Thormann-Huber Medical Director Technical Director CFO Professor Dr. Arndt Rolfs Dr. Hans Paul Walliser

Dr. Florian Fischer

Chairman Dr. Gerhard Ries; General Partner, BioMedInvest AG, Basel; Switzerland Members of the Board of Directors Dr. Annegret de Baey-Diepolder; Partner, TVM Capital, Munich; Germany Dr. Jrg Neerman; Partner, LSP, Life Sciences Partners; Munich; Germany Dr. Domenico Valerio; Partner; AESCAP Venture Management BV, Amsterdam, Netherlands Prof. Dr. Walter Dettling; Chairman of the Board of Directors Inotech Biotechnologies Ltd., Basel, Switzerland

Xenometrix produces and distributes today's most advanced Ames mutagenicity assays (microfluctuation assays) and cytotoxicity screening kits designed to reduce the amount of test compound, hands-on time and consumables. The Ames II / Ames MPF Microfluctuation Assays are all modifications of the traditional Ames plate incorporation assay. Nicole Weiland-Jggi, PhD in Biochemistry, CEO Jens Germer, PhD in Microbiology. Marketing and Sales International Sini Flckiger, PhD in Biochemistry. Production, Development, Quality Assurance, Ames II, Ames MPF, In Cytotox Product Range, umuC. Markus Kamber, PhD in Cell Biology and Immunology. Production, Development, Quality Assurance, Technical Support In Cytotox Product Range, Ames II, Ames MPF and umuC. Nicole Gahler, Logistics and Orders Chris Wessner, Administration Hans Jrgen Schmidt, Marketing and Sales for Switzerland, Germany, Austria, Israel, Middle East

Xenometrix AG Switzerland Tel. +41 61 482 14 34 Fax +41 61 482 20 72 info@xenometrix.ch

As an International Contract Research Organisation (CRO), Swiss Pharma Contract Ltd. Offers a Variety of Services Focused on Clinical Pharmacology and Clinical Research, Ranging from First Testing of a New Drug in Man to Post-Marketing Clinical Studies. Rolf Pokorny, M.D., M.Sc. Head of Clinical Research / Biometrics Michael Seiberling, M.D. Head of Clinical Pharmacology Thierry Kamtchoua, M.D. Head of Clinics Aline Cossy-Gantner, Business Development Director

Swiss Pharma Contract Ltd. Switzerland Tel +41 / 61 / 487 24 00, Fax +41 / 61 / 487 24 01